Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections

Table 3

Clinical cure and microbiologic eradication outcomes of ZTI-01 (intravenous fosfomycin) versus piperacillin-tazobactam in patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), due to baseline pathogens with resistant phenotypes.

Phenotype	Clinical cure^a		Microbiologic eradication^b
	Fosfomycin n/N (%)	Piperacillin-tazobactam n/N (%)	Fosfomycin n/N (%)	Piperacillin-tazobactam n/N (%)
ESBL	52/56 (93%)	51/55 (93%)	32/58 (55%)	27/57 (47%)
Aminoglycoside-resistant	29/30 (97%)	29/31 (94%)	20/30 (67%)	12/32 (38%)
CRE	9/9 (100%)	11/13 (85%)	5/9 (56%)	4/13 (31%)
MDR	34/37 (92%)	28/31 (90%)	20/37 (54%)	12/33 (36%)

Table adapted from reference [3]. ESBL, extended-spectrum β-lactamase (≥2 μg/mL MIC for aztreonam, ceftazidime, or ceftriaxone); aminoglycoside-resistant (gentamicin ≥8 μg/mL MIC or amikacin ≥32 μg/mL MIC); CRE, carbapenem-resistant Enterobacterales (≥4 μg/mL MIC for imipenem or meropenem); MDR, multidrug-resistant (resistant to at least one agent in ≥3 antimicrobial classes); N, total number of patients in specified cohort; n, number of patients achieving specified outcome. ^aClinical cure defined as complete resolution or significant improvement of signs and symptoms such that no further antimicrobial therapy is warranted. ^bMicrobiological eradication is defined as a urine culture or blood culture, if applicable, demonstrating that the bacterial pathogen identified at baseline has decreased from ≥10⁵ CFU/mL to <10⁴ CFU/mL.